Impact of Metabolic Syndrome on Myocardial Status in ICU Patients

Background:

Metabolic Syndrome (MetS) represents a constellation of interrelated cardiovascular risk factors that significantly impact patient outcomes in critical care settings. Despite its recognized prevalence among patients with acute myocardial infarction (AMI) admitted to intensive care units (ICU), the precise relationship between MetS and in-hospital clinical outcomes remains incompletely understood. This study aims to evaluate the prevalence of MetS in critically ill AMI patients and elucidate its association with myocardial dysfunction, clinical severity, and in-hospital mortality.

Methods:

This systematic observational study examined data on patients’ demographics, clinical characteristics, and clinical outcomes. The investigation focused on prevalence rates, patient characteristics including age, gender, body mass index, waist circumference, and comorbidities, as well as in-hospital outcomes such as mortality, heart failure, and major adverse cardiovascular events (MACE).

Results:

The prevalence of MetS in patients with AMI in the ICU setting demonstrates remarkable consistency across diverse populations, ranging from 46% to 68.3% [1, 2]. Patients with MetS exhibit distinct demographic profiles, being more likely to be female and presenting with elevated body mass index (BMI), increased waist circumference, and higher prevalence of hypertension and diabetes mellitus. While the association between MetS and all-cause in-hospital mortality remains equivocal in some studies, cardiovascular-specific mortality demonstrates a significant elevation (P = 0.03), accompanied by increased rates of congestive heart failure and recurrent myocardial ischemia [1, 3]. Component analysis reveals that specific MetS elements, particularly hyperglycemia and BMI ≥28 kg/m², function as independent predictors of MACE [2]. The underlying pathophysiological mechanisms involve complex interactions between systemic inflammation, endothelial dysfunction, and prothrombotic states, collectively contributing to progressive myocardial dysfunction.

Conclusion:

Metabolic Syndrome constitutes a substantial health burden in critically ill patients with AMI, conferring elevated risk for specific in-hospital complications. The pathophysiological cascade involves systemic inflammation, endothelial dysfunction, and prothrombotic states that drive myocardial fibrosis and ventricular remodeling, ultimately culminating in myocardial dysfunction. These findings underscore the imperative for early identification and aggressive management of MetS and its individual components to optimize outcomes in this high-risk population. Further large-scale prospective investigations are warranted to definitively establish the prognostic implications of MetS in the ICU setting and to develop targeted therapeutic interventions.

Dr. Mohamed Wasfy is an intensivist specializing in critical care medicine research. He holds MSc in both critical care medicine from Ain Shams university (Egypt) and cardiology from Menoufia university (Egypt) Epidemiology. Dr. Wasfy has worked in most of the pioneers hospitals in Egypt and American hospital Dubai as long as Fujairah hospital in UAE and has published previously a paper titled Cystatin C in coronary artery disease patients. He is currently a senior intensive care specialist in Fujairah hospital, UAE.